NCT04079790View on ClinicalTrials.gov

Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 4, 2019

Primary Completion Date

November 25, 2019

Study Completion Date

November 25, 2019

Conditions
Infections, Bacterial
Interventions
DRUG

Gepotidacin

Tablets containing gepotidacin mesylate with a unit dose of 750 mg will be administered orally with 240 milliliter (mL) of water.

DRUG

Placebo

Tablets containing unit dose of placebo matching of gepotidacin will be administered orally with 240 mL of water.

Trial Locations (1)

89113

GSK Investigational Site, Las Vegas

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT04079790 - Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects | Biotech Hunter | Biotech Hunter